<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IMR</journal-id>
<journal-id journal-id-type="hwp">spimr</journal-id>
    <journal-title>Journal of International Medical Research</journal-title>
<issn pub-type="ppub">0300-0605</issn>
<issn pub-type="epub">1473-2300</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0300060513476999</article-id>
<article-id pub-id-type="publisher-id">10.1177_0300060513476999</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Circulating endothelial progenitor cells in gynaecological cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kim</surname><given-names>Yoon Byoung</given-names></name>
<xref ref-type="corresp" rid="corresp1-0300060513476999"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Chung</surname><given-names>Ye Won</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Bae</surname><given-names>Hyo Sook</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Lee</surname><given-names>Jae Kwan</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Lee</surname><given-names>Nak Woo</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Lee</surname><given-names>Kyu Wan</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Song</surname><given-names>Jae Yun</given-names></name>
</contrib>
</contrib-group>
<aff id="aff1-0300060513476999">Department of Obstetrics and Gynaecology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea</aff>
<author-notes>
<corresp id="corresp1-0300060513476999">Dr Yoon Byoung Kim, Department of Obstetrics and Gynaecology, Korea University Anam Hospital, Korea University College of Medicine, 126-1, 5 ga, Anam-dong, Seongbuk-gu, Seoul 136-705, Republic of Korea. Email: <email>yuni105@korea.ac.kr</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>41</volume>
<issue>2</issue>
<fpage>293</fpage>
<lpage>299</lpage>
<history>
<date date-type="received"><day>30</day><month>8</month><year>2012</year></date>
<date date-type="accepted"><day>21</day><month>10</month><year>2012</year></date>
</history>
<permissions>   
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
    <copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec12-0300060513476999">
<title>Objectives</title>
<p>To compare the frequency and absolute numbers of circulating endothelial progenitor cells (EPCs) in healthy control subjects and patients with gynaecological cancer, and to test the hypothesis that cancer treatment lowers EPC numbers.</p>
</sec>
<sec id="sec13-0300060513476999">
<title>Methods</title>
<p>Patients with cervical or ovarian cancer and healthy control subjects provided peripheral blood samples for the isolation of mononuclear cells. EPCs were identified by quadruple immunofluorescence staining and flow cytometry as CD45<sup>–</sup>/CD34<sup>+</sup>/CD133<sup>+</sup>/vascular endothelial growth factor receptor 2 (VEGFR2)<sup>+</sup> cells.</p>
</sec>
<sec id="sec14-0300060513476999">
<title>Results</title>
<p>In total, 28 participants were enrolled. Circulating EPCs were present at higher frequencies (and in greater absolute numbers) in patients with cervical or ovarian cancer (<italic>n</italic> = 14) than in controls (<italic>n</italic> = 14). Concurrent chemoradiation therapy or surgery significantly reduced the frequency and number of EPCs in patients with gynaecological cancer, compared with pretreatment levels.</p>
</sec>
<sec id="sec15-0300060513476999">
<title>Conclusions</title>
<p>EPC levels decline throughout cancer treatment; their measurement may therefore be a useful surrogate marker to monitor treatment response.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Cervical cancer</kwd>
<kwd>CD34<sup>+</sup></kwd>
<kwd>CD45<sup>–</sup></kwd>
<kwd>CD133<sup>+</sup></kwd>
<kwd>circulating endothelial progenitor cells</kwd>
<kwd>ovarian cancer</kwd>
<kwd>VEGFR2<sup>+</sup></kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0300060513476999" sec-type="intro"><title>Introduction</title>
<p>Tumour growth and metastasis are closely related to abnormal angiogenesis and neovascularization. The mechanisms of tumour angiogenesis are unclear, but studies have shown that circulating endothelial progenitor cells (EPCs) play an important role in this process.<sup><xref ref-type="bibr" rid="bibr1-0300060513476999">1</xref>,<xref ref-type="bibr" rid="bibr2-0300060513476999">2</xref></sup></p>
<p>Circulating EPCs have been suggested as potential surrogate markers of angiogenesis in cancer and in other vascular diseases.<sup><xref ref-type="bibr" rid="bibr3-0300060513476999">3</xref></sup> Increases in circulating EPC levels might reflect the abnormally high turnover of tumour endothelium in invasive cancer and the disordered nature of angiogenesis, and may relate to tumour vascular volume. Tumours encourage the mobilization of circulating progenitor cells from the bone marrow, which may be important in tumour vascularity.<sup><xref ref-type="bibr" rid="bibr1-0300060513476999">1</xref>,<xref ref-type="bibr" rid="bibr2-0300060513476999">2</xref>,<xref ref-type="bibr" rid="bibr4-0300060513476999">4</xref>,<xref ref-type="bibr" rid="bibr5-0300060513476999">5</xref></sup></p>
<p>Circulating EPCs can be detected and quantified in peripheral blood samples by flow cytometric analysis, using cell surface markers of hematopoietic stem cells including CD34, CD133 and vascular endothelial growth factor receptor 2 (VEGFR2).<sup><xref ref-type="bibr" rid="bibr6-0300060513476999">6</xref></sup> The numbers of circulating EPCs have been shown to be increased in malignant diseases such as breast cancer, ovarian cancer, nonsmall cell lung cancer and lymphoma.<sup><xref ref-type="bibr" rid="bibr7-0300060513476999">7</xref><xref ref-type="bibr" rid="bibr8-0300060513476999"/><xref ref-type="bibr" rid="bibr9-0300060513476999"/><xref ref-type="bibr" rid="bibr10-0300060513476999"/><xref ref-type="bibr" rid="bibr11-0300060513476999"/>–<xref ref-type="bibr" rid="bibr12-0300060513476999">12</xref></sup></p>
<p>The kinetics of circulating EPCs and endothelial cells in response to antiangiogenic treatment have been studied in animal models.<sup><xref ref-type="bibr" rid="bibr2-0300060513476999">2</xref></sup> There is evidence that metronomic chemotherapy and inhibitors of the VEGFR signalling pathway can suppress circulating EPC numbers.<sup><xref ref-type="bibr" rid="bibr13-0300060513476999">13</xref><xref ref-type="bibr" rid="bibr14-0300060513476999"/><xref ref-type="bibr" rid="bibr15-0300060513476999"/><xref ref-type="bibr" rid="bibr16-0300060513476999"/><xref ref-type="bibr" rid="bibr17-0300060513476999"/>–<xref ref-type="bibr" rid="bibr18-0300060513476999">18</xref></sup> In addition, there may be a correlation between circulating EPC numbers and disease status or treatment.<sup><xref ref-type="bibr" rid="bibr19-0300060513476999">19</xref></sup></p>
<p>The aim of the current study was to compare circulating EPC numbers and frequencies in healthy individuals with those in patients with gynaecological cancer, in order to test the hypothesis that cancer treatment (such as tumour debulking surgery or concurrent chemoradiation therapy [CCRT]) may reduce circulating EPC numbers.</p>
</sec>
<sec id="sec2-0300060513476999" sec-type="methods"><title>Patients and methods</title>
<sec id="sec3-0300060513476999"><title>Study population</title>
<p>The study recruited patients first diagnosed with cervical or ovarian cancer between December 2011 and April 2012, who underwent treatment at the Department of Obstetrics and Gynaecology, Korea University Anam Hospital, Seoul, Republic of Korea. Tumours were classified according to the 1987 staging criteria of the International Federation of Gynecology and Obstetrics (FIGO).<sup><xref ref-type="bibr" rid="bibr20-0300060513476999">20</xref></sup> Healthy women with no previous cancer diagnosis (who were attending the Department of Obstetrics and Gynaecology, Korea University Anam Hospital for routine screening) were recruited as control subjects. No attempt was made to age match the study groups.</p>
<p>Written informed consent was obtained from all participants prior to blood collection. The study was approved by the Institutional Review Board, Korea University Anam Hospital, Seoul, Republic of Korea.</p>
</sec>
<sec id="sec4-0300060513476999"><title>Blood collection</title>
<p>All study participants provided peripheral blood samples. Patients with cervical cancer who were undergoing CCRT provided blood samples before treatment and after every third cycle of chemotherapy (40 mg/m<sup>2</sup> cisplatin, once per week). Patients with cervical cancer who underwent surgery instead of CCRT, and those with ovarian cancer (all of whom underwent surgery only) provided blood samples before and after surgery. Control subjects provided blood samples on enrolment.</p>
</sec>
<sec id="sec5-0300060513476999"><title>PBMC isolation</title>
<p>Peripheral blood mononuclear cells (PBMCs) were isolated from 15–20-ml whole blood samples, which had been collected in ethylenediaminetetra-acetic acid-coated sterile tubes. Blood was mixed with an equal volume of phosphate buffered saline (PBS, pH, 7.4), layered on Ficoll® reagent (1077 g/ml) and centrifuged at 400 <bold><italic>g</italic></bold> for 20 min at 15–20°C. The buffy coat containing mononuclear cells was recovered, mixed with ≤ 50 ml PBS and centrifuged at 300 <bold><italic>g</italic></bold> for 10 min at 15–20°C. The supernatant was discarded and the cell pellet was resuspended in 1 ml PBS. A further 19 ml of PBS was added and samples were centrifuged at 300 <bold><italic>g</italic></bold> for 10 min at 15–20°C. Viable cells were counted by trypan blue staining.</p>
</sec>
<sec id="sec6-0300060513476999"><title>Flow cytometry</title>
<p>Endothelial progenitor cells were identified by quadruple immunofluorescence staining and flow cytometry. In brief, 1 × 10<sup>6</sup> PBMCs (in 200 µl) were incubated for 30 min at 4°C with 2 μl each of fluorescein isothiocyanate-conjugated mouse antihuman CD45, phycoerythrin-conjugated mouse antihuman VEGFR2, peridinin chloropyll protein-conjugated mouse antihuman CD34, and allophycocyanin-conjugated mouse antihuman CD133 (all from BD Biosciences, Heidelberg, Germany). Cells were washed three times in BD FACS<sup>TM</sup> Buffer (BD Biosciences) at 4°C (5 min each wash) then fixed in 1% paraformaldehyde. Parallel cell samples were stained with 1 μl propidium iodide for 5 min to validate the live cell population. A FACSCaliber™ flow cytometer (BD Biosciences) was used to acquire ≥ 2 × 10<sup>5</sup> region-one events, and data were analysed with WinMDI software, version 2.9 (Scripps Research Institute, San Diego, CA, USA). A representative flow cytometric gating strategy for the identification of EPCs is shown in <xref ref-type="fig" rid="fig1-0300060513476999">Figure 1</xref>. EPCs were identified as CD45<sup>–</sup>/CD34<sup>+</sup>/CD133<sup>+</sup>/VEGFR2<sup>+</sup> cells.
<fig id="fig1-0300060513476999" position="float"><label>Figure 1.</label><caption><p>Representative flow cytometric plots indicating the strategy for identification of circulating endothelial progenitor cells (EPCs). EPCs were defined as CD45<sup>–</sup>/CD34<sup>+</sup>/CD133<sup>+</sup>/vascular endothelial growth factor receptor 2 (VEGFR2)<sup>+</sup> cells. Flow cytometry was performed using sequential gatings: (A) forward (FSC) and side scatter (SSC) plot of cells and gating region G1 to include all mononuclear cells while excluding cell debris; (B) CD45<sup>–</sup> gating to exclude lymphocytes; (C) Region R7 comprising CD45<sup>–</sup>/CD34<sup>+</sup> cells; (D) Double-positive CD133<sup>+</sup>/VEGFR2<sup>+</sup> gating identifies ECPs in region R8.</p></caption><graphic xlink:href="10.1177_0300060513476999-fig1.tif"/>
</fig></p>
</sec>
<sec id="sec7-0300060513476999"><title>Statistical analyses</title>
<p>Data were expressed as mean ± SD; between-group comparisons were made using Student’s <italic>t-</italic>test. Statistical analyses were performed with SPSS® software, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows®. A <italic>P</italic>-value &lt; 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="sec8-0300060513476999" sec-type="results"><title>Results</title>
<p>The study included six patients with cervical cancer (CCRT <italic>n</italic> = 4; surgery <italic>n</italic> = 2), eight patients with ovarian cancer, and 14 healthy control subjects. Demographic and clinical characteristics of patients are shown in <xref ref-type="table" rid="table1-0300060513476999">Table 1</xref>.
<table-wrap id="table1-0300060513476999" position="float"><label>Table 1.</label><caption><p>Demographic and clinical characteristics of patients with cervical or ovarian cancer and healthy control subjects, included in a study to examine the effect of cancer and cancer treatment on frequency and numbers of circulating endothelial progenitor cell.</p></caption>
<graphic alternate-form-of="table1-0300060513476999" xlink:href="10.1177_0300060513476999-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Characteristic</th>
<th align="center">Cervical cancer group</th>
<th align="center">Ovarian cancer group</th>
<th align="center">Control group</th>
</tr>
<tr><th align="center"><italic>n</italic> = 6</th>
<th align="center"><italic>n</italic> = 8</th>
<th align="center"><italic>n</italic> = 14</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Age, years</td>
<td align="center">58.5 ± 8.85</td>
<td align="center">54.0 ± 19.55</td>
<td align="center">26 ± 5.73</td>
</tr>
<tr>
<td>Parity</td>
<td align="center">2.7 ± 0.82</td>
<td align="center">2.3 ± 1.49</td>
<td align="center">0 (0)</td>
</tr>
<tr>
<td>Cancer type</td>
</tr>
<tr>
<td> SCC</td>
<td align="center">5 (83.3)</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td> Adenocarcinoma</td>
<td align="center">1 (16.7)</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td> Serous carcinoma</td>
<td align="center">–</td>
<td align="center">7 (87.5)</td>
<td align="center">–</td>
</tr>
<tr>
<td> Mucinous carcinoma</td>
<td align="center">–</td>
<td align="center">1 (12.5)</td>
<td align="center">–</td>
</tr>
<tr>
<td>FIGO stage<sup><xref ref-type="bibr" rid="bibr20-0300060513476999">20</xref></sup></td>
</tr>
<tr>
<td> IB</td>
<td align="center">2 (33.3)</td>
<td align="center">0</td>
<td align="center">–</td>
</tr>
<tr>
<td> IIA</td>
<td align="center">1 (16.7)</td>
<td align="center">0</td>
<td align="center">–</td>
</tr>
<tr>
<td> IIB</td>
<td align="center">3 (50.0)</td>
<td align="center">0</td>
<td align="center">–</td>
</tr>
<tr>
<td> IIIC</td>
<td align="center">0</td>
<td align="center">8 (100)</td>
<td align="center">–</td>
</tr>
<tr>
<td>Treatment</td>
</tr>
<tr>
<td> CCRT</td>
<td align="center">4 (66.7)</td>
<td align="center">0</td>
<td align="center">–</td>
</tr>
<tr>
<td> Surgery</td>
<td align="center">2 (33.3)</td>
<td align="center">8 (100)</td>
<td align="center">–</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0300060513476999"><p>Data presented as mean ± SD or <italic>n</italic> (%) of patients.</p></fn>
<fn id="table-fn2-0300060513476999"><p>SCC, squamous cell carcinoma; FIGO, International Federation of Gynecology and Obstetrics; CCRT, concurrent chemoradiation therapy.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>The frequency (but not the numbers) of circulating EPCs was significantly lower in control subjects than in patients with cervical cancer (<italic>P</italic> = 0.004, <xref ref-type="table" rid="table2-0300060513476999">Table 2</xref>). CCRT (three and six cycles) resulted in a significant decrease in EPC frequency from baseline (baseline vs three cycles <italic>P</italic> = 0.009, baseline vs six cycles <italic>P</italic> = 0.016, three cycles vs six cycles <italic>P</italic> = 0.025; <xref ref-type="table" rid="table2-0300060513476999">Table 2</xref>). Surgical removal of cancer tissue significantly reduced the frequency of circulating EPCs compared with preoperative values (<italic>P</italic> = 0.044; <xref ref-type="table" rid="table2-0300060513476999">Table 2</xref>). There were no significant differences in EPC numbers associated with any cervical cancer treatment.
<table-wrap id="table2-0300060513476999" position="float"><label>Table 2.</label><caption><p>Frequency and numbers of circulating endothelial progenitor cells (EPCs) in patients with cervical cancer before and after concurrent chemoradiation therapy (CCRT) or surgical treatment, and in healthy control subject.</p></caption>
<graphic alternate-form-of="table2-0300060513476999" xlink:href="10.1177_0300060513476999-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="4">EPCs</th>
<th rowspan="2">Control group</th>
<th rowspan="2">Cervical cancer group</th>
<th colspan="3">CCRT group</th>
<th colspan="2">Surgery group</th>
</tr>
<tr><th colspan="3" rowspan="2"><italic>n</italic> = 4</th>
<th colspan="2" rowspan="2"><italic>n</italic> = 2</th>
</tr>
<tr><th rowspan="2"><italic>n</italic> = 14</th>
<th rowspan="2"><italic>n</italic> = 6</th>
</tr>
<tr><th>Baseline</th>
<th>3 cycles</th>
<th>6 cycles</th>
<th>Preoperative</th>
<th>Postoperative</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Frequency, %</td>
<td>0.002 ± 0.002</td>
<td>0.032 ± 0.014<sup><xref ref-type="table-fn" rid="table-fn1-0300060513476999">a</xref></sup></td>
<td>0.034 ± 0.014</td>
<td>0.011 ± 0.005<sup>b</sup></td>
<td>0.005 ± 0.004<sup>c,d</sup></td>
<td>0.0157 ± 0.0003</td>
<td>0.005 ± 0.001<sup>e</sup></td>
</tr>
<tr>
<td>Cells/ml blood</td>
<td>21 ± 22</td>
<td>543 ± 773</td>
<td>634 ± 976</td>
<td>422 ± 660</td>
<td>85 ± 41</td>
<td>361 ± 174</td>
<td>56 ± 23</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0300060513476999"><p>Data presented as mean ± SD.</p></fn>
<fn id="table-fn4-0300060513476999"><label>a</label><p><italic>P</italic> &lt; 0.01 versus control group, <sup>b</sup><italic>P</italic> &lt; 0.01 versus CCRT baseline, <sup>c</sup><italic>P</italic> &lt; 0.05 versus CCRT baseline, <sup>d</sup><italic>P</italic> &lt; 0.05 versus 3 cycles of CCRT, <sup>e</sup><italic>P</italic> &lt; 0.05 versus preoperative data; Student’s <italic>t</italic>-test.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Patients with ovarian cancer were found to have significantly higher EPC numbers and higher frequencies of EPCs than control subjects (<italic>P</italic> = 0.000035 for frequency, <italic>P</italic> = 0.01 for cell numbers; <xref ref-type="table" rid="table3-0300060513476999">Table 3</xref>). Surgery significantly lowered both cell numbers and frequency, compared with preoperative values (<italic>P</italic> = 0.0001 for frequency and <italic>P</italic> = 0.005 for cell numbers; <xref ref-type="table" rid="table3-0300060513476999">Table 3</xref>). These postoperative reductions in cell numbers and frequency were observed in all patients with ovarian cancer included in the study.
<table-wrap id="table3-0300060513476999" position="float"><label>Table 3.</label><caption><p>Frequency and numbers of circulating endothelial progenitor cells (EPCs) in patients with ovarian cancer before and after surgical treatment, and in healthy control subject.</p></caption>
<graphic alternate-form-of="table3-0300060513476999" xlink:href="10.1177_0300060513476999-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="3">EPCs</th>
<th>Control group</th>
<th colspan="2">Ovarian cancer group</th>
</tr>
<tr><th rowspan="2"><italic>n</italic> = 14</th>
<th colspan="2"><italic>n</italic> = 8</th>
</tr>
<tr><th>Preoperative</th>
<th>Postoperative</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Frequency, %</td>
<td>0.002 ± 0.002</td>
<td>0.012 ± 0.002<sup><xref ref-type="table-fn" rid="table-fn6-0300060513476999">a</xref></sup></td>
<td>0.0005 ± 0.0001<sup><xref ref-type="table-fn" rid="table-fn6-0300060513476999">b</xref></sup></td>
</tr>
<tr>
<td>Cells/ml blood</td>
<td>24 ± 23</td>
<td>146 ± 108<sup><xref ref-type="table-fn" rid="table-fn6-0300060513476999">a</xref></sup></td>
<td>62 ± 47<sup><xref ref-type="table-fn" rid="table-fn6-0300060513476999">b</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0300060513476999"><p>Data presented as mean ± SD.</p></fn>
<fn id="table-fn6-0300060513476999"><p><sup>a</sup><italic>P</italic> &lt; 0.05 vs control group, <sup>b</sup><italic>P</italic> &lt; 0.01 vs preoperative data; Student’s <italic>t</italic>-test.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec9-0300060513476999" sec-type="discussion"><title>Discussion</title>
<p>Endothelial progenitor cells differentiate from haemangioblasts during the development of mesodermal precursors, and further differentiate into mature endothelial cells to form the lining of blood vessels in a process known as vasculogenesis. In the course of vasculogenesis, EPCs mobilize from bone marrow to peripheral tissue sites in response to endogenous or exogenous signals, and autocrine/paracrine activation results in differentiation, proliferation and vascular growth.<sup><xref ref-type="bibr" rid="bibr5-0300060513476999">5</xref></sup> EPCs can be detected in peripheral and cord blood, and play important roles in physiological processes such as neovascularization, wound healing, tissue regeneration following ischaemia (e.g. myocardial infarction) and tissue remodelling.<sup><xref ref-type="bibr" rid="bibr3-0300060513476999">3</xref></sup> In tumour pathogenesis, however, EPC recruitment is thought to mediate aberrant vasculogenesis, and facilitate tumour growth and metastasis.<sup><xref ref-type="bibr" rid="bibr21-0300060513476999">21</xref></sup></p>
<p>Circulating EPCs cannot be successfully defined with a single surface antigen, instead requiring the use of several markers (including VEGFR2, CD31, CD34 and CD133) for their detection in peripheral blood.<sup><xref ref-type="bibr" rid="bibr22-0300060513476999">22</xref></sup> The majority of studies concerning the correlation of circulating EPCs with gynaecological cancer have used double-positive flow cytometry analysis (e.g. CD133/VEGFR2 in breast cancer and CD34/VEGFR2 in ovarian or cervical cancer).<sup><xref ref-type="bibr" rid="bibr8-0300060513476999">8</xref>,<xref ref-type="bibr" rid="bibr11-0300060513476999">11</xref>,<xref ref-type="bibr" rid="bibr23-0300060513476999">23</xref></sup> The approach of the current study was to use four concurrent markers (CD45<sup>–</sup>/VEGFR2<sup>+</sup>/CD34<sup>+</sup>/CD133<sup>+</sup>) to increase the accuracy of EPC detection.</p>
<p>Studies have found high levels of circulating EPCs to be associated with breast, ovarian and pancreatic tumours.<sup><xref ref-type="bibr" rid="bibr8-0300060513476999">8</xref>,<xref ref-type="bibr" rid="bibr11-0300060513476999">11</xref>,<xref ref-type="bibr" rid="bibr24-0300060513476999">24</xref></sup> Circulating EPCs (CD133<sup>+</sup>/VEGFR<sup>+</sup>) were shown to be significantly more numerous in advanced breast cancer than in early stage disease, and these EPC numbers declined significantly following chemotherapy.<sup><xref ref-type="bibr" rid="bibr8-0300060513476999">8</xref></sup> EPCs (CD34<sup>+</sup>/VEGFR<sup>+</sup>) were also present at higher levels in more advanced cases of ovarian cancer.<sup><xref ref-type="bibr" rid="bibr11-0300060513476999">11</xref></sup> Circulating EPCs were present at a greater frequency in patients with either cervical or ovarian cancer than in control subjects, in the present study. In addition, treatment (CCRT or surgery) lowered EPC frequency in all patients.</p>
<p>Endothelial progenitor cells may represent a potential new treatment modality for tumours, as their role in angiogenesis could be a pharmacological target. Studies suggest that circulating EPCs may be useful markers for predicting therapeutic outcome or prognosis.<sup><xref ref-type="bibr" rid="bibr8-0300060513476999">8</xref></sup> In addition, animal studies have shown that circulating EPC numbers decline in response to antiangiogenic therapy such as anti-VEGFR2 antibodies, and chemotherapeutic drug response can be measured, in part, by levels of EPCs in peripheral blood.<sup><xref ref-type="bibr" rid="bibr25-0300060513476999">25</xref></sup></p>
<p>In conclusion, the present study demonstrates that circulating EPCs are significantly more numerous, and more frequent, in patients with gynaecological cancer than in healthy control subjects. As EPCs decline throughout treatment they may be useful surrogate markers to monitor cancer treatment response. Further research, involving larger patient populations, is needed in order to validate whether EPCs have such clinical and therapeutic potential.</p>
</sec>
</body>
<back>
<sec id="sec10-0300060513476999"><title>Declaration of conflicting interest</title>
<p>The authors declare that there are no conflicts of interest.</p>
</sec>
<sec id="sec11-0300060513476999"><title>Funding</title>
<p>This study was supported by a grant from <grant-sponsor>Korea University Hospital</grant-sponsor>.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0300060513476999"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lyden</surname><given-names>D</given-names></name><name><surname>Hattori</surname><given-names>K</given-names></name><name><surname>Dias</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth</article-title>. <source>Nat Med</source> <year>2001</year>; <volume>7</volume>: <fpage>1194</fpage>–<lpage>1201</lpage>.</citation></ref>
<ref id="bibr2-0300060513476999"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dome</surname><given-names>B</given-names></name><name><surname>Dobos</surname><given-names>J</given-names></name><name><surname>Tovari</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Circulating bone marrow-derived endothelial progenitor cells: characterization, mobilization, and therapeutic considerations in malignant disease</article-title>. <source>Cytometry A</source> <year>2008</year>; <volume>73</volume>: <fpage>186</fpage>–<lpage>193</lpage>.</citation></ref>
<ref id="bibr3-0300060513476999"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asahara</surname><given-names>T</given-names></name><name><surname>Masuda</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization</article-title>. <source>Circ Res</source> <year>1999</year>; <volume>85</volume>: <fpage>221</fpage>–<lpage>228</lpage>.</citation></ref>
<ref id="bibr4-0300060513476999"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goon</surname><given-names>PK</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name><name><surname>Boos</surname><given-names>CJ</given-names></name><etal/></person-group>. <article-title>Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer</article-title>. <source>Neoplasia</source> <year>2006</year>; <volume>8</volume>: <fpage>79</fpage>–<lpage>88</lpage>.</citation></ref>
<ref id="bibr5-0300060513476999"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>AL</given-names></name><name><surname>Bangalore-Prakash</surname><given-names>P</given-names></name><name><surname>Rajoria</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Endothelial progenitor cell biology in disease and tissue regeneration</article-title>. <source>J Hematol Oncol</source> <year>2011</year>; <volume>4</volume>: <fpage>24</fpage>–<lpage>24</lpage>.</citation></ref>
<ref id="bibr6-0300060513476999"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Masouleh</surname><given-names>BK</given-names></name><name><surname>Baraniskin</surname><given-names>A</given-names></name><name><surname>Schmiegel</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Quantification of circulating endothelial progenitor cells in human peripheral blood: establishing a reliable flow cytometry protocol</article-title>. <source>J Immunol Methods</source> <year>2010</year>; <volume>357</volume>: <fpage>38</fpage>–<lpage>42</lpage>.</citation></ref>
<ref id="bibr7-0300060513476999"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goon</surname><given-names>PK</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name><name><surname>Stonelake</surname><given-names>PS</given-names></name><etal/></person-group>. <article-title>Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index</article-title>. <source>Neoplasia</source> <year>2009</year>; <volume>11</volume>: <fpage>771</fpage>–<lpage>779</lpage>.</citation></ref>
<ref id="bibr8-0300060513476999"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naik</surname><given-names>RP</given-names></name><name><surname>Jin</surname><given-names>D</given-names></name><name><surname>Chuang</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer</article-title>. <source>Breast Cancer Res Treat</source> <year>2008</year>; <volume>107</volume>: <fpage>133</fpage>–<lpage>138</lpage>.</citation></ref>
<ref id="bibr9-0300060513476999"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blann</surname><given-names>AD</given-names></name><name><surname>Balakrishnan</surname><given-names>B</given-names></name><name><surname>Shantsila</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: a comparison with plasma vascular markers</article-title>. <source>Prostate</source> <year>2011</year>; <volume>71</volume>: <fpage>1047</fpage>–<lpage>1053</lpage>.</citation></ref>
<ref id="bibr10-0300060513476999"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>R</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Nakano</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer</article-title>. <source>J Cancer Res Clin Oncol</source> <year>2011</year>; <volume>137</volume>: <fpage>1849</fpage>–<lpage>1857</lpage>.</citation></ref>
<ref id="bibr11-0300060513476999"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Quantity and clinical relevance of circulating endothelial progenitor cells in human ovarian cancer</article-title>. <source>J Exp Clin Cancer Res</source> <year>2010</year>; <volume>29</volume>: <fpage>27</fpage>–<lpage>27</lpage>.</citation></ref>
<ref id="bibr12-0300060513476999"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oki</surname><given-names>Y</given-names></name><name><surname>Younes</surname><given-names>A</given-names></name></person-group>. <article-title>Endothelial progenitor cells in non-Hodgkin’s lymphoma</article-title>. <source>Haematologica</source> <year>2007</year>; <volume>92</volume>: <fpage>433</fpage>–<lpage>434</lpage>.</citation></ref>
<ref id="bibr13-0300060513476999"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Capillo</surname><given-names>M</given-names></name><name><surname>Mancuso</surname><given-names>P</given-names></name><name><surname>Gobbi</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors</article-title>. <source>Clin Cancer Res</source> <year>2003</year>; <volume>9</volume>: <fpage>377</fpage>–<lpage>382</lpage>.</citation></ref>
<ref id="bibr14-0300060513476999"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schuch</surname><given-names>G</given-names></name><name><surname>Heymach</surname><given-names>JV</given-names></name><name><surname>Nomi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells</article-title>. <source>Cancer Res</source> <year>2003</year>; <volume>63</volume>: <fpage>8345</fpage>–<lpage>8350</lpage>.</citation></ref>
<ref id="bibr15-0300060513476999"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertolini</surname><given-names>F</given-names></name><name><surname>Paul</surname><given-names>S</given-names></name><name><surname>Mancuso</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells</article-title>. <source>Cancer Res</source> <year>2003</year>; <volume>63</volume>: <fpage>4342</fpage>–<lpage>4346</lpage>.</citation></ref>
<ref id="bibr16-0300060513476999"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaked</surname><given-names>Y</given-names></name><name><surname>Bertolini</surname><given-names>F</given-names></name><name><surname>Man</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis</article-title>. <source>Cancer Cell</source> <year>2005</year>; <volume>7</volume>: <fpage>101</fpage>–<lpage>111</lpage>.</citation></ref>
<ref id="bibr17-0300060513476999"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaked</surname><given-names>Y</given-names></name><name><surname>Emmenegger</surname><given-names>U</given-names></name><name><surname>Man</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity</article-title>. <source>Blood</source> <year>2005</year>; <volume>106</volume>: <fpage>3058</fpage>–<lpage>3061</lpage>.</citation></ref>
<ref id="bibr18-0300060513476999"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaked</surname><given-names>Y</given-names></name><name><surname>Ciarrocchi</surname><given-names>A</given-names></name><name><surname>Franco</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors</article-title>. <source>Science</source> <year>2006</year>; <volume>313</volume>: <fpage>1785</fpage>–<lpage>1787</lpage>.</citation></ref>
<ref id="bibr19-0300060513476999"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dome</surname><given-names>B</given-names></name><name><surname>Timar</surname><given-names>J</given-names></name><name><surname>Ladanyi</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: from biology to therapy</article-title>. <source>Crit Rev Oncol Hematol</source> <year>2009</year>; <volume>69</volume>: <fpage>108</fpage>–<lpage>124</lpage>.</citation></ref>
<ref id="bibr20-0300060513476999"><label>20</label><citation citation-type="journal"><collab>International Federation of Gynecology and Obstetrics</collab>. <article-title>Changes in definitions of clinical staging for carcinoma of the cervix and ovary</article-title>. <source>Am J Obstet Gynecol</source> <year>1987</year>; <volume>156</volume>: <fpage>263</fpage>–<lpage>264</lpage>.</citation></ref>
<ref id="bibr21-0300060513476999"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>F</given-names></name><name><surname>Ha</surname><given-names>XQ</given-names></name></person-group>. <article-title>Effect of endothelial progenitor cells in neovascularization and their application in tumor therapy</article-title>. <source>Chin Med J (Engl)</source> <year>2010</year>; <volume>123</volume>: <fpage>2454</fpage>–<lpage>2460</lpage>.</citation></ref>
<ref id="bibr22-0300060513476999"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>SS</given-names></name><name><surname>Solomon</surname><given-names>MA</given-names></name><name><surname>McCoy</surname><given-names>Jr</given-names><suffix>JP</suffix></name></person-group>. <article-title>Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry</article-title>. <source>Cytometry B Clin Cytom</source> <year>2005</year>; <volume>64</volume>: <fpage>1</fpage>–<lpage>8</lpage>.</citation></ref>
<ref id="bibr23-0300060513476999"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raida</surname><given-names>M</given-names></name><name><surname>Weiss</surname><given-names>T</given-names></name><name><surname>Leo</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Circulating endothelial progenitor cells are inversely correlated with the median oxygen tension in the tumor tissue of patients with cervical cancer</article-title>. <source>Oncol Rep</source> <year>2006</year>; <volume>16</volume>: <fpage>597</fpage>–<lpage>601</lpage>.</citation></ref>
<ref id="bibr24-0300060513476999"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>XJ</given-names></name><name><surname>Moro</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>CXCR2-dependent endothelial progenitor cell mobilization in pancreatic cancer growth</article-title>. <source>Transl Oncol</source> <year>2011</year>; <volume>4</volume>: <fpage>20</fpage>–<lpage>28</lpage>.</citation></ref>
<ref id="bibr25-0300060513476999"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garmy-Susini</surname><given-names>B</given-names></name><name><surname>Varner</surname><given-names>JA</given-names></name></person-group>. <article-title>Circulating endothelial progenitor cells</article-title>. <source>Br J Cancer</source> <year>2005</year>; <volume>93</volume>: <fpage>855</fpage>–<lpage>858</lpage>.</citation></ref>
</ref-list>
</back>
</article>